Ratings Medibank Private Limited

Equities

MPL

AU000000MPL3

Market Closed - Australian S.E. Other stock markets 11:40:03 29/04/2024 am IST			5-day change	1st Jan Change
3.6 ^AUD	+1.12%		-1.10%	+1.12%

06/03	Morgan Stanley Adjusts Medibank Private’s Price Target to AU$3.84 From AU$3.66, Keeps at Equalweight	MT
23/02	Jarden Research Downgrades Medibank Private to Neutral From Overweight, Keeps Price Target at AU$3.75	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.
According to Refinitiv, the company's ESG score for its industry is good.

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
The company is one of the best yield companies with high dividend expectations.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company appears highly valued given the size of its balance sheet.
The average consensus view of analysts covering the stock has deteriorated over the past four months.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Life & Health Insurance

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
MEDIBANK PRIVATE LIMITED	+1.12%	6.39B		C+
BUPA ARABIA FOR COOPERATIVE INSURANCE COMPANY	+12.56%	9.58B		B-
THE COMPANY FOR COOPERATIVE INSURANCE	+11.67%	5.82B		C
OSCAR HEALTH, INC.	+90.82%	4.16B		-
NIB HOLDINGS LIMITED	+1.49%	2.31B		B+
TRUPANION, INC.	-20.93%	1.01B		C
RELIGARE ENTERPRISES LIMITED	+3.85%	862M	-	D+
THE MEDITERRANEAN AND GULF COOPERATIVE INSURANCE AND REINSURANCE COMPANY	+78.12%	718M	-	C
AMANA COOPERATIVE INSURANCE COMPANY	+3.36%	155M	-	-
PT LIPPO GENERAL INSURANCE TBK	-8.15%	68.79M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes